金河生物科技股份有限公司投资者关系活 动记录表 编号：2023-003 | --- | --- | --- | |------------------------|--------------------------------------------------|----------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □媒体采访 □新闻发布会 □路演活动 | □业绩说明会 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 公司证券事务代表 | 李鹏程 | | | 公司证券事务中心 | 孙雪茹 | | | 公司证券事务中心 | 王三毛 | | | 公司证券事务中心 | 杨婧楠 | | | 国海证券股份有限公司 | 熊子兴 | | | 华泰证券股份有限公司 | 曹鸣东 | | | 华西证券股份有限公司 | 张伟明 | | 活动参与人员 | 华西证券股份有限公司中国长城资产管理股份有限公司 | 蔺培文 李晓东 | | | 中国长城资产管理股 ...

金河生物科技股份有限公司投资者关系活动记录表 编号：2023-002 您好！金霉素如果在牛羊的适用上获批，其他厂家 的金霉素也会受益，这对金霉素产品的市场空间拓展是 一个利好，蛋糕做大了，大家都可以多分一点，是行业 的好事，岂不美哉！ 5、董事长，您就像一个老大哥，弟弟说一句，如果单 纯的把股票，看做是一个融资的渠道，那是大错特错 了，我真心的希望，您能重视资本市场，对企业发展 的真正意义，希望金河一切都好，长风破浪会有时， 直挂云帆济沧海。 回复： 公司上市是公司发展的一个里程碑，公司从此走上 了高速发展的轨道，先后并购了杭州荐量疫苗公司、美 国普泰克疫苗公司，进入了动物疫苗领域。上市解决了 公司融资难的问题，为公司未来的发展打开了空间，提 供了足够的资金支持，公司融资是为了把企业做大做 | | | | □特定对象调研 | □分析师会议 | | | --- | --- | --- | --- | --- | --- | | 投资者关系活动类 | □媒体采访  业绩说明会 | | | | | | 别 | □新闻发布会 □路演活动 | | | | | | | □现场参观 | | | | | | 活动参与人员 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 527,286,393.92, representing a 1.45% increase compared to CNY 519,765,405.51 in the same period last year[5] - Net profit attributable to shareholders was CNY 36,920,074.20, marking a 16.20% increase from CNY 31,771,635.03 year-on-year[5] - Basic earnings per share rose to CNY 0.0473, up 16.22% from CNY 0.0407 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 527,286,393.92, an increase of 1.0% compared to CNY 519,765,405.51 in Q1 2022[28] - Net profit for Q1 2023 was CNY 40,439,624.37, a decrease of 6.0% from CNY 43,496,662.89 in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 34,595,261.09, a decrease from CNY 41,952,788.32 in the previous year, representing a decline of approximately 17.5%[30] Cash Flow - The net cash flow from operating activities decreased by CNY 58,163,894.77, a decline of 158.00% compared to the previous year[15] - The net cash flow from operating activities was negative at CNY -21,352,026.70, compared to a positive CNY 36,811,868.07 in the same period last year[33] - The cash outflow from operating activities totaled CNY 505,294,806.80, compared to CNY 483,337,561.32 in the previous year, an increase of about 4.5%[33] - The company did not report any cash inflow from investment activities, resulting in a net cash flow from investment activities of CNY -60,603,411.71, similar to the previous year's CNY -64,565,989.89[33] - The net cash flow from financing activities was CNY 80,682,022.28, significantly higher than CNY 21,158,538.49 in the previous year, marking an increase of approximately 281.5%[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,573,098,902.44, reflecting a 1.50% increase from CNY 4,505,582,532.92 at the end of the previous year[5] - The company's total liabilities increased to CNY 2,112,802,128.28, up from CNY 2,080,365,862.98 at the beginning of the year[26] - The company's cash and cash equivalents decreased to CNY 421,418,848.00 from CNY 491,367,885.89 at the beginning of the year, representing a decline of 14.2%[24] - The total cash and cash equivalents at the end of the period were CNY 408,318,743.68, down from CNY 492,542,177.26, a decrease of about 17.1%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 31,495[19] - The largest shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., holds 30.98% of the shares, amounting to 241,758,670 shares[19] - The company plans to implement a restricted stock incentive plan to attract and retain talent, approved by the board on April 21, 2023[22] Operational Metrics - Total operating costs for Q1 2023 were CNY 492,684,043.93, up 3.0% from CNY 477,748,716.72 in the same period last year[28] - Revenue from sales of goods and services received cash of CNY 450,600,293.78, down from CNY 483,989,302.99, indicating a decrease of about 6.5%[32] - Accounts receivable increased to CNY 431,826,292.69, up 5.4% from CNY 409,497,970.35 at the start of the year[24] - Inventory rose to CNY 733,229,854.64, an increase of 8.5% compared to CNY 675,908,511.03 at the beginning of the year[25] - Short-term borrowings increased to CNY 1,270,276,378.56, up 1.9% from CNY 1,246,476,832.69 at the start of the year[26] Other Financial Metrics - The weighted average return on equity increased by 0.36 percentage points to 1.65% compared to 1.29% in the previous year[5] - The company reported a significant increase in interest income, which rose by CNY 1,413,270.37, a 501.81% increase year-on-year[10] - Credit impairment losses increased by CNY 1,571,788.96, representing a 421.29% rise due to extended payment terms from some downstream customers[10] - Other comprehensive income attributable to shareholders decreased by CNY 3,670,579.37, a reduction of 282.29% due to foreign exchange fluctuations[14] - Cash received from investment decreased by ¥30,300,000.00, a decline of 100.00% compared to the previous year, due to the absence of similar business activities[16] - Cash received from other financing activities decreased by ¥1,250,000.00, also a decline of 100.00%, primarily due to the previous year's bank refund of loan deposits[16] - Cash paid for financing activities decreased by ¥70,100,570.65, a reduction of 99.29%, as there were no similar business activities this period[16] - Dividend payments increased by ¥4,713,005.48, an increase of 53.37%, mainly due to the rise in average borrowing amounts[16] - The net effect of exchange rate changes on cash and cash equivalents was an increase of ¥735,386.23, a growth of 35.51% year-on-year[17] - Research and development expenses for Q1 2023 were CNY 15,311,156.03, a decrease of 20.4% from CNY 19,280,982.50 in Q1 2022[29]

Financial Performance - The company's operating revenue for 2022 was ¥2,122,705,317.42, representing a 2.15% increase compared to ¥2,077,988,730.16 in 2021[6]. - The net profit attributable to shareholders decreased by 19.63% to ¥75,543,369.47 in 2022 from ¥93,992,380.84 in 2021[6]. - The basic earnings per share fell by 28.35% to ¥0.0968 in 2022, down from ¥0.1351 in 2021[6]. - The total assets increased by 10.85% to ¥4,505,582,532.92 at the end of 2022, compared to ¥4,064,525,859.70 at the end of 2021[6]. - The company's cash flow from operating activities decreased by 18.63% to ¥124,471,194.04 in 2022 from ¥152,978,505.57 in 2021[6]. - The weighted average return on equity decreased by 1.72 percentage points to 3.09% in 2022 from 4.81% in 2021[6]. - The company reported a net profit of -¥26,914,451.49 in Q4 2022, contrasting with profits in the first three quarters[23]. - The company reported a net profit attributable to shareholders of 75.54 million yuan, a decrease of 19.63% compared to the previous year[40]. - The overall revenue for the reporting period increased by CNY 16.83 million, a growth of 2.34% compared to the same period last year[49]. - The net profit for the reporting period decreased by CNY 8.53 million, a decline of 33.60% year-on-year[49]. Revenue Breakdown - Revenue from veterinary chemical drugs was 983.93 million yuan, a decrease of 7.71%, accounting for 46.35% of total revenue[40]. - Revenue from veterinary biological products increased by 13.19% to 330.17 million yuan, making up 15.55% of total revenue[40]. - The environmental business saw a revenue increase of 25.07%, reaching 107.58 million yuan, which accounted for 5.07% of total revenue[40]. - The revenue from the agricultural processing industry increased by CNY 55.02 million, a growth of 10.76% year-on-year[55]. - Domestic sales accounted for 65.61% of total revenue, increasing by 7.84% compared to the previous year[56]. - Direct sales revenue reached CNY 1,578,151,290, a year-on-year increase of 29.06%[57]. - The revenue from Pharmgate Inc. increased by CNY 88.06 million, a growth of 22.88% compared to the previous year[52]. - The revenue from the environmental business increased by CNY 28.04 million, representing an 18.51% growth compared to the previous year[51]. Cost and Expenses - The company's operating costs reached 1,508.91 million CNY, a year-on-year increase of 5.75%, with veterinary chemical drugs accounting for 46.90% of total operating costs[43]. - The gross profit margin decreased by 2.42 percentage points compared to the previous year due to the increase in operating costs outpacing revenue growth[43]. - The total cost of raw materials for veterinary chemical drugs was approximately 400.69 million, accounting for 56.61% of the total operating costs, showing a slight decrease of 0.18% compared to 2021[63]. - The total sales expenses increased by 6.70% to approximately 130.72 million in 2022, compared to 122.51 million in 2021[68]. - Research and development expenses rose by 13.89% to approximately 82.28 million in 2022, compared to 72.25 million in 2021, reflecting increased investment in vaccine projects and new product development[68]. Market and Competition - The veterinary medicine industry is experiencing increased concentration, with the top 31 companies accounting for 80.4% of total sales in the biological products sector[29]. - The company is facing intensified competition and opportunities in the veterinary medicine market due to regulatory changes and increased foreign investment[30]. - The company is actively expanding into the pet medicine sector, with plans to increase product variety and scope in the future[33]. - The company is focusing on strategic adjustments in product structure to enhance product value and expand business scale[46]. Research and Development - The company has a strong emphasis on research and development, with four major technology platforms for vaccine production and significant advancements in product upgrades[37]. - R&D investment increased by 39.78% to ¥122,010,847.05 in 2022, representing 5.75% of operating revenue[71]. - The number of R&D personnel rose to 252, a 4.13% increase from 2021, with a notable increase in PhD holders by 20%[71]. - The company is focusing on new product development in veterinary vaccines, with several new products expected to be launched in the coming years[33]. Corporate Governance - The company maintains independent operations and governance, with no interference from controlling shareholders in decision-making processes[126]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[126]. - The company has established a robust financial management system, including independent accounting and tax reporting[130]. - The company complies with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[127]. Environmental Responsibility - The company adheres to various environmental standards, including GB13271-2014J for boiler emissions and GB37823-2019 for pharmaceutical industry emissions[172]. - The company has implemented real-time monitoring of emissions for various pollutants, ensuring adherence to environmental standards[176]. - The company has established a zero discharge wastewater project, ensuring that treated water meets the required pollution discharge standards[176]. - In 2022, the company invested CNY 1.353 million in environmental governance facilities and paid CNY 0.6981 million in environmental protection tax[178]. Future Outlook - The company plans to continue focusing on product development and market expansion to mitigate the impact of market fluctuations[58]. - The company aims to become a technology-driven, leading animal health company within the next 5-10 years[115]. - The company anticipates a revenue growth target of 20% for the next fiscal year, driven by new product launches and market penetration strategies[89]. - The company plans to enhance its supply chain efficiency, targeting a 15% reduction in operational costs by 2024[137].

证券代码：002688 证券简称：金河生物 公告编号:2023-013 金河生物科技股份有限公司 关于举行2022年年度报告网上业绩说明会的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）定于2023年5月10日（星 期三）下午15:00至17:00在全景网举办2022年度业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次年度业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 9 日 15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问 题征集专题页面。敬请广大投资者通过全景网系统提交您所关注的问题，便于 公司在业绩说明会上对投资者普遍关注的问题进行回答，提升此次业绩说明会 的针对性。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广 ...

Group 1: Company Overview - The company, Jinhe Biological, has significant sales in both domestic and international markets, with foreign market revenue accounting for 50,983.09 million in 2014, representing a substantial portion of its main business income [1] - The main products are used as feed additives to promote animal production and prevent diseases, and as purified hydrochloride for treating animal diseases [3] Group 2: Product Characteristics - The key features of feed-grade gold mycin include: (1) mature production technology with high efficacy and relatively low cost; (2) broad antibacterial spectrum effective against both Gram-negative and Gram-positive bacteria; (3) no cross-use in humans and animals, avoiding cross-resistance; (4) high safety with low-dose long-term use not causing drug residues; (5) minimal compatibility issues with other feed additives or veterinary drugs [3] Group 3: Strategic Acquisitions - The acquisition of Panfield's operating assets aims to utilize its sales channels to strengthen the company's market position and serve as a strategic development reserve for future expansion [4] Group 4: Future Development Goals - The company envisions becoming a world-leading animal health product enterprise, focusing on consolidating its advantages in biological fermentation and drug feed additives, while actively developing new products in the field of novel veterinary biological products [4]

Group 1: Company Competitive Advantages - The company has over 20 years of experience in biological fermentation production, making it one of the largest producers of feed-grade gold mycelium globally [1] - Key competitive advantages include technological superiority, regional advantages, customer and market network marketing advantages, product quality advantages, and brand advantages [2] Group 2: Target Consumer Groups - The main consumer groups for the company's products include domestic and international animal health product companies, feed companies, and poultry and livestock farms [2] Group 3: Stock Issuance Progress - As of November 26, 2015, the China Securities Regulatory Commission approved the company's application for a non-public stock issuance, with further steps pending the receipt of formal approval documents [2] Group 4: Strategic Development Goals - The company's strategic goal is to create a world-leading animal health product enterprise, consolidating its advantages in biological fermentation and drug feed additives while innovating and expanding into new veterinary biological products [3]

Group 1: Company Overview - The company, Jinhe Biological Technology Co., Ltd., has over 20 years of development and primarily engages in the production and sales of feed additives, with a focus on feed-grade chlortetracycline [2][3] - Jinhe is the largest global producer of feed-grade chlortetracycline [3] Group 2: Product Functions - Feed-grade chlortetracycline is used to promote animal growth, improve feed conversion rates, and prevent animal diseases. It can reduce mortality rates and increase weight gain and feed conversion rates when fed at low doses [3] Group 3: Fundraising and Financials - The total amount raised from the non-public offering of shares is 47.34 million yuan, with the net proceeds intended to supplement the company's working capital after deducting issuance costs. Approval from the China Securities Regulatory Commission is still pending [3][4] Group 4: Raw Material Impact - The cost of corn, which constitutes approximately 30% to 50% of the company's main business costs, is influenced by various factors including climate, national corn reserve policies, and supply-demand relationships [4]

Group 1: Company Product Advantages - The main advantages of the company's feed additive product,金霉素, include broad-spectrum antibacterial effects, low cost, high safety, and no residue [4] - The product has a low risk of cross-infection between humans and animals, and fewer drug interactions [4] Group 2: Market Performance - The company has signed a five-year procurement agreement with Zoetis in the U.S. for金霉素, effective until December 31, 2019, with good execution so far [4] - Domestic demand for金霉素 is expected to grow due to the intensification of pig farming and standardized drug use [4] Group 3: Industry Barriers - Key barriers to entering the feed additive industry include strict production licensing regulations, technical barriers, financial barriers, and brand reliability [5] Group 4: Future Development Plans - The company aims to become a world-leading animal health product enterprise, focusing on enhancing its advantages in biological fermentation and feed additives [5] - Plans include developing new products, extending the product line, expanding business scale, and enhancing global market influence [5] - The company is also exploring opportunities in environmental protection, particularly in wastewater treatment, to create new profit growth points [5]

Group 1: Company Overview - The company operates in the fields of veterinary drug additives, animal vaccines, animal health products, corn starch processing, and environmental technology [2] - The vision is to create a world-leading animal health product enterprise, enhancing core competitiveness and expanding business scale [2] Group 2: Future Development Plans - The company aims to strengthen its advantages in biological fermentation and drug feed additives while actively developing new products to increase added value [2] - Plans to expand into wastewater treatment as a new profit growth point [2][3] Group 3: Environmental Technology - Inner Mongolia Jinhe Environmental Technology Co., Ltd. focuses on high-concentration industrial wastewater treatment, with a daily treatment capacity of 10,000 tons [3] - The company employs a third-party governance model to improve treatment efficiency and reduce pollution control costs [3] Group 4: Financial Information - The lock-up period for the non-public stock issuance is three years, with no performance commitments or leverage involved [3] Group 5: Product Information - The main function of feed-grade gold mycin is to promote animal growth, improve feed conversion rates, and prevent animal diseases [3]